Trial Profile
A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Acronyms AiME - 03
- Sponsors Hospira
- 20 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Apr 2014 New trial record